Zura Bio’s (ZURA) “Outperform” Rating Reaffirmed at Wedbush

Zura Bio (NASDAQ:ZURA)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a report released on Wednesday,Benzinga reports. They presently have a $15.00 price objective on the stock. Wedbush’s target price would suggest a potential upside of 184.95% from the stock’s previous close.

A number of other research analysts have also recently commented on the company. Oppenheimer reduced their target price on Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Chardan Capital increased their price objective on Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, March 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Zura Bio in a report on Wednesday, April 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Zura Bio has a consensus rating of “Moderate Buy” and a consensus price target of $10.75.

Zura Bio Price Performance

ZURA stock traded down $0.64 during midday trading on Wednesday, reaching $5.26. The company had a trading volume of 164,089 shares, compared to its average volume of 832,263. The firm has a 50-day moving average price of $4.47 and a 200-day moving average price of $5.29. The company has a market capitalization of $499.45 million, a P/E ratio of -5.00 and a beta of 0.03. Zura Bio has a 1 year low of $1.06 and a 1 year high of $7.44.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.05). On average, equities analysts predict that Zura Bio will post -0.76 EPS for the current year.

Hedge Funds Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP purchased a new position in Zura Bio in the 4th quarter worth approximately $30,000. Squarepoint Ops LLC boosted its stake in shares of Zura Bio by 34.6% during the fourth quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock valued at $177,000 after purchasing an additional 8,680 shares during the period. Bank of America Corp DE grew its holdings in shares of Zura Bio by 31.9% in the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Zura Bio by 3.4% in the first quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock worth $1,864,000 after buying an additional 10,200 shares during the period. Finally, Scientech Research LLC bought a new stake in Zura Bio during the 3rd quarter valued at $45,000. 61.14% of the stock is currently owned by institutional investors.

Zura Bio Company Profile

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.